---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-22-298895"
form_type: "8-K"
ticker: "AGIO"
cik: "0001439222"
company_name: "AGIOS PHARMACEUTICALS, INC."
filed_at: "2022-12-06T23:59:59+00:00"
generated_at: "2026-06-21T08:47:15.411757+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Agios appoints Tsveta Milanova as CCO effective Jan 3, 2023; Richa Poddar departs Dec 31, 2022

## Summary
- Tsveta Milanova named Chief Commercial Officer, will succeed Richa Poddar effective Jan 3, 2023.
- Milanova previously SVP US Commercial at Alexion; brings rare disease commercial launch experience.
- Poddar will receive $450K severance plus 2022 target bonus and 12-month COBRA coverage.
- Milanova's base salary $510K, target bonus 45%, sign-on bonus $150K, plus equity grants.

## SEC filing metadata
- accession: 0001193125-22-298895
- form_type: 8-K
- ticker: AGIO
- cik: 0001439222
- company_name: AGIOS PHARMACEUTICALS, INC.
- filed_at: 2022-12-06T23:59:59+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 5.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1439222/000119312522298895/0001193125-22-298895-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1439222/000119312522298895/d407010d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-22-298895
- JSON: https://secwatch.observer/filing/0001193125-22-298895.json
- Plain text: https://secwatch.observer/filing/0001193125-22-298895.txt

## Key facts
- Executive change
  Tsveta Milanova was appointed as Chief Commercial Officer at AGIOS PHARMACEUTICALS, INC..
  - Action: appointed
  - Role: Chief Commercial Officer
  source text: the Company appointed Tsveta Milanova as the Company’s Chief Commercial Officer, effective as of January 3, 2023
  evidence_url: https://www.sec.gov/Archives/edgar/data/1439222/000119312522298895/0001193125-22-298895-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.